An interesting method has recently been published by Iovance Biotherapeutics, Inc., concerning the expansion of TILs from tumor cells using, among others, CD95 agonists, for the treatment of diseases such as cancer (WO2018129332) [277, 278, 366]. This evidence concerns the gene FAS and neoplasm.